Aprogen Medicines Inc. (KRX: 007460)
South Korea
· Delayed Price · Currency is KRW 1,020.00
-11.00 (-1.07%)
Nov 18, 2024, 3:30 PM KST
Aprogen Medicines Income Statement
Financials in millions KRW. Fiscal year is January - December.
Millions KRW. Fiscal year is Jan - Dec.
Fiscal Year | TTM | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | 2018 - 2014 |
|---|---|---|---|---|---|---|---|
Period Ending | Jun '24 Jun 30, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 | Dec '20 Dec 31, 2020 | Dec '19 Dec 31, 2019 | 2018 - 2014 |
| Operating Revenue | 150,918 | 150,578 | 78,349 | 26,296 | 127,143 | 78,249 | Upgrade
|
| Other Revenue | -0 | -0 | -0 | 0 | - | - | Upgrade
|
| Revenue | 150,918 | 150,578 | 78,349 | 26,296 | 127,143 | 78,249 | Upgrade
|
| Revenue Growth (YoY) | 9.29% | 92.19% | 197.95% | -79.32% | 62.48% | 53.29% | Upgrade
|
| Cost of Revenue | 94,583 | 116,380 | 78,143 | 31,513 | 93,148 | 59,616 | Upgrade
|
| Gross Profit | 56,335 | 34,198 | 205.9 | -5,217 | 33,994 | 18,633 | Upgrade
|
| Selling, General & Admin | 72,758 | 66,140 | 67,621 | 43,833 | 26,983 | 14,727 | Upgrade
|
| Research & Development | 49,520 | 42,817 | 38,561 | 32,780 | 1,029 | 1,871 | Upgrade
|
| Other Operating Expenses | 905.76 | 872.25 | 733.32 | 760.94 | 690.81 | 298.43 | Upgrade
|
| Operating Expenses | 146,435 | 129,168 | 117,150 | 90,590 | 31,150 | 17,858 | Upgrade
|
| Operating Income | -90,099 | -94,970 | -116,944 | -95,807 | 2,844 | 775.07 | Upgrade
|
| Interest Expense | - | -631.84 | -9,906 | -21,764 | -5,231 | -9,147 | Upgrade
|
| Interest & Investment Income | 6,461 | 3,683 | 3,031 | 2,206 | 10,933 | 4,546 | Upgrade
|
| Earnings From Equity Investments | - | - | -1,210 | -1,734 | - | - | Upgrade
|
| Currency Exchange Gain (Loss) | 355.93 | 30.76 | -113.93 | -44.53 | -466.78 | 130 | Upgrade
|
| Other Non Operating Income (Expenses) | -2,361 | -428.55 | 22,216 | -379.06 | -35,343 | 33,827 | Upgrade
|
| EBT Excluding Unusual Items | -85,642 | -92,316 | -102,926 | -117,523 | -27,264 | 30,131 | Upgrade
|
| Gain (Loss) on Sale of Investments | -988.24 | 341.93 | -3,244 | -9,036 | -11,605 | -21,146 | Upgrade
|
| Gain (Loss) on Sale of Assets | -236.21 | 30.3 | -235.89 | -287.07 | -3.45 | -2.78 | Upgrade
|
| Asset Writedown | -1,402 | -2,271 | -9,162 | -223.61 | -241.5 | -511.53 | Upgrade
|
| Other Unusual Items | - | -1,024 | -42.95 | 7,728 | -2.67 | 8,452 | Upgrade
|
| Pretax Income | -88,268 | -95,239 | -115,611 | -119,341 | -39,117 | 16,923 | Upgrade
|
| Income Tax Expense | 6,445 | 2,044 | 473.8 | -111.74 | -6,448 | -1,403 | Upgrade
|
| Earnings From Continuing Operations | -94,713 | -97,283 | -116,085 | -119,229 | -32,668 | 18,326 | Upgrade
|
| Net Income to Company | -94,713 | -97,283 | -116,085 | -119,229 | -32,668 | 18,326 | Upgrade
|
| Minority Interest in Earnings | 46,014 | 41,664 | 17,428 | 25,309 | -13,822 | -29,165 | Upgrade
|
| Net Income | -48,700 | -55,619 | -98,657 | -93,920 | -46,490 | -10,839 | Upgrade
|
| Net Income to Common | -48,700 | -55,619 | -98,657 | -93,920 | -46,490 | -10,839 | Upgrade
|
| Shares Outstanding (Basic) | 250 | 236 | 201 | 173 | 57 | 46 | Upgrade
|
| Shares Outstanding (Diluted) | 250 | 236 | 202 | 173 | 57 | 46 | Upgrade
|
| Shares Change (YoY) | -27.89% | 16.69% | 16.73% | 206.64% | 24.06% | 168.99% | Upgrade
|
| EPS (Basic) | -194.51 | -235.50 | -490.37 | -541.72 | -822.24 | -237.83 | Upgrade
|
| EPS (Diluted) | -194.98 | -236.00 | -497.41 | -541.72 | -822.24 | -237.83 | Upgrade
|
| Free Cash Flow | -64,304 | -83,669 | -133,101 | -119,132 | 19,957 | -8,969 | Upgrade
|
| Free Cash Flow Per Share | -256.84 | -354.27 | -657.66 | -687.14 | 352.97 | -196.80 | Upgrade
|
| Gross Margin | 37.33% | 22.71% | 0.26% | -19.84% | 26.74% | 23.81% | Upgrade
|
| Operating Margin | -59.70% | -63.07% | -149.26% | -364.34% | 2.24% | 0.99% | Upgrade
|
| Profit Margin | -32.27% | -36.94% | -125.92% | -357.17% | -36.57% | -13.85% | Upgrade
|
| Free Cash Flow Margin | -42.61% | -55.57% | -169.88% | -453.05% | 15.70% | -11.46% | Upgrade
|
| EBITDA | -61,391 | -65,899 | -88,552 | -70,545 | 7,152 | 4,026 | Upgrade
|
| EBITDA Margin | -40.68% | -43.76% | -113.02% | -268.27% | 5.63% | 5.15% | Upgrade
|
| D&A For EBITDA | 28,708 | 29,071 | 28,392 | 25,262 | 4,308 | 3,251 | Upgrade
|
| EBIT | -90,099 | -94,970 | -116,944 | -95,807 | 2,844 | 775.07 | Upgrade
|
| EBIT Margin | -59.70% | -63.07% | -149.26% | - | 2.24% | 0.99% | Upgrade
|
| Advertising Expenses | - | - | - | - | 4,369 | 2,483 | Upgrade
|
Source: S&P Capital IQ. Standard template. Financial Sources.